Skip to content
KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer

KRAS Mutation: Powerful Molecular Predictor of Cetuximab Response in Patients With Metastatic Colorectal Cancer

Get the podcast

Pierre Laurent-Puig Bill Hait REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris COMMEN

The Audio Journal of Oncology
Pierre Laurent-Puig


Pierre Laurent-Puig

Bill Hait


Bill Hait

REFERENCE: ABSTRACT: 5671, American Association for Cancer Research, April 14-18, 2007, Los Angeles
PIERRE LAURENT-PUIG, Hôpital Européen Georges Pompidou, Paris
COMMENT: BILL HAIT, Johnson & Johnson, Raritan, NJ
The presence of the KRAS mutation in tumor samples from patients with colorectal cancer gives clear prognostic information about the effectiveness of therapy with the epidermal growth factor receptor inhibitor cetuximab. This is the finding of a group from Paris reported at the American Association for Cancer Research 2007 Annual Meeting held in Los Angeles. Peter Goodwin discussed research findings with Pierre Laurent-Puig.
Bill Hait, President of the American Association for Cancer Research, commented on the findings from Paris discussed by Pierre Laurent-Puig about the value of the KRAS mutation in predicting the response of patients with metastatic colorectal cancer to therapy with cetuximab.

To listen this episode please go to ASCO Audio Journal of Oncology in Advance Presentations.

Tags

aboutaudiocancercetuximabcolorectalcommentsepisodefindingsinhibitorinhibitorsjournalmetastaticmutationpatientreceptorreportreportstherapiestherapytumors

Next in AACR

All 45 interviews

Interview 42 of 45

Virus Plus Cytokine Fight Primary and Metastatic Cancer

Virus Plus Cytokine Fight Primary and Metastatic Cancer

Paul Fisher REFERENCE: Meet the Professor Session, AACR 2007, Los Angeles PAUL FISHER, Columbia University, New York Patients with cancer could soon be treated with adenoviruses capable of infecting b

15 August 2007

Related Episodes

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

4 Jun 2026
11 min